Latest Content

Clinicians and pharmacists at Temple and Penn discuss barriers to multidisciplinary obesity care, from ICD-10 coding gaps to prior authorization burdens.

Independent investigations found that venetoclax-based combination regimens achieved high response and strong MRD negativity in newly diagnosed leukemias.

Epcoritamab shows high first-line responses and MRD negativity in chemo-ineligible older DLBCL patients, alone or with R-mini-CHOP.

SEER and Medicare data project rising DLBCL and MCL cases through 2032, intensifying payer strain and demand for Brukinsa, Calquence, and CAR-T access.

ASCO real-world oncology data show racial disparities in pain management, with delayed meds and fewer strong opioids for Black and Asian patients.

Deloitte's midyear analysis shows internal confidence rising even as external uncertainty over policy, tariffs, and reimbursement persists for biopharma and medtech.

FDA approves palbociclib (Ibrance) for HR+, HER2+ metastatic breast cancer maintenance, based on phase 3 PATINA data showing a 24% reduction in progression risk.

Interviews with patients living with generalized myasthenia gravis (MG) in the US revealed areas of increased burden in these patients.

A Medicare claims analysis found zanubrutinib was associated with significantly longer treatment duration and overall survival vs acalabrutinib and ibrutinib.